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The Impact of Contingency Management on Quality of Life
Among Cocaine Abusers With and Without Alcohol Dependence
Leonardo F. Andrade, Ph.D., Sheila M. Alessi, Ph.D., and Nancy M. Petry, Ph.D.*
University of Connecticut School of Medicine
Abstract
The use of quality of life measures (QOL) in substance abuse treatment research is important
because it may lead to a broader understanding of patients’ health status and effects of
interventions. Despite the high rates of comorbid cocaine and alcohol use disorders, little is known
about the QOL of this population, and even less about the impact of an efficacious behavioral
treatment, contingency management (CM), on QOL. In this study, data from three clinical trials
were retrospectively analyzed to examine QOL in outpatient cocaine abusers with and without
alcohol dependence (AD) and the impact of CM on QOL over time as a function of AD status.
Patients were randomized to standard care (n = 115) or standard care plus CM (n = 278) for 12
weeks. QOL was assessed at baseline and Months 1, 3, 6, and 9. At treatment initiation, AD
patients had lower QOL total scores and they scored lower on several subscale scores than those
without AD. CM treatment was associated with improvement in QOL regardless of AD status.
These data suggest that CM produces benefits that go beyond substance abuse outcomes, and they
support the use of QOL indices to capture information related to treatment outcomes.
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In the general population, 84% of individuals with lifetime cocaine abuse have also had an
alcohol use disorder.1 In treatment-seeking cocaine-dependent individuals, approximately
60% present with lifetime alcohol dependence.2–4 Individuals with concurrent cocaine and
alcohol dependence show greater behavioral, psychological, and psychiatric impairment
than individuals with either disorder alone. Concurrent dependence is associated with
greater severity of psychosocial problems,2, 3 other drug use,2, 5, 6 and psychosis and
depression.5–7
Among patients who seek treatment for cocaine use, concomitant cocaine-alcohol use
disorders can negatively impact treatment outcomes. For example, Schmitz et al.8 found that
dual cocaine-alcohol dependence was associated with more frequent self-reported cocaine
use and greater psychiatric symptom severity at the end of substance abuse treatment than
cocaine dependence alone. In another sample of treated cocaine abusers, Carroll et al.9 also
reported that patients with concurrent alcohol dependence had poorer psychiatric and
substance use outcomes than those without alcohol dependence.
Treatment for cocaine dependence is designed to impact drug use, and it also tends to have
effects on reducing psychiatric symptoms. Another factor increasingly considered in
treatment outcomes research generally is quality of life (QOL).10 QOL assessments measure
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individuals’ perceptions and reactions to their physical, psychological, and social
functioning.11 Some QOL instruments are relatively generic (e.g., SF-36 survey; Quality
Metric, Inc.).12 Others are designed to cover specific domains of QOL and/or apply to a
particular population (e.g., Brogly et al.13). In a prior study14 and the present one, we used
the Quality of Life Inventory (QOLI).15, 16 The QOLI is unique in that it measures a
respondent's subjective satisfaction and importance on 17 domains of life (e.g., friendship,
home, love relationship), yielding a global score weighted by the extent to which each
domain is important to the respondent.16, 17
There are relatively few examples of QOL research in the drug abuse compared to general
health care literature.18, 19 Most QOL research conducted in substance abusing populations
has examined the effects of alcohol use disorder.20, 21 In general, the few existing studies
show an inverse relationship between the presence of alcohol dependence and QOL. For
example, McKenna et al.22 used the SF-36 to assess the QOL of patients previously treated
for alcohol, and they reported that patients diagnosed with alcohol dependence have lower
QOL than those with abuse and compared to the normative population. Using the same
instrument, Volk et al.23 evaluated the QOL of primary care patients with alcohol problems
and also found that, relative to abusers, alcohol dependent patients have significantly poorer
QOL. Scores on other QOL instruments are also lower among patients admitted to an
alcohol detoxification unit 24 relative to normative values.
With respect to cocaine and QOL, fewer studies exist. In one investigation, 20 the QOL of
individuals initiating an outpatient randomized clinical trial for substance abuse was
assessed via SF-36. The sample, primarily dependent on cocaine or alcohol, showed more
impairment than the normative US population. Lower QOL is also evident in non-clinical
drug dependent samples. 25, 26 For example, in a study in crack-cocaine smokers, 25 the
presence of dependence and frequency of crack cocaine consumption were negatively
correlated with QOL. Further, hospitalized psychiatric patients with cocaine dependence
have lower QOL (defined by Lehman's Quality of Life Interview scores) than psychiatric
patients with alcohol or other drug dependences.27
Importantly, changes in QOL over time can be used to gain improved understanding of
treatment outcomes. For example, abstinence is associated with improvements in QOL over
time in a population of outpatient cocaine abusers14 and alcohol drinkers, 28 as well as
alcohol dependent patients, 29 although some older studies found no effect of abstinence on
QOL.30, 31 QOL may also predict relapse. In one study conducted with inner city residents
with severe history of dependence on crack and/or heroin, baseline QOL satisfaction scores
served as a predictor of remission at 1 to 2 years later.32
As suggested above and elsewhere,18, 19, 33 more widespread adoption of QOL measures in
drug abuse research and treatment might serve the important role of capturing information
related to patients’ functioning in addition to more commonly measured outcomes (e.g.,
percent of abstinent days). That is, the use of QOL measures in substance abuse treatment
research may lead to a broader understanding of overall health status and treatment
effects.11, 20, 21, 34
Contingency management (CM) is a treatment with demonstrated efficacy for improving
substance abuse treatment outcomes.35, 36 CM is based on operant-conditioning principles in
that if reinforcers are delivered contingent on objective demonstration of a target behavior,
such as drug abstinence, the behavior will increase in frequency. Typically, the reinforcers
are vouchers exchangeable for goods or services 35 or opportunities to win prizes of
different magnitudes.37 CM interventions have demonstrated efficacy for promoting
abstinence from cocaine4 and alcohol,38 as well as other substances.39–41 Only one known
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CM study has evaluated the impact of CM on QOL. Petry et al.14 found that CM, compared
to standard care, was associated with increased QOL during the treatment period and
throughout follow-up. Furthermore, durations of abstinence achieved during treatment
mediated the impact of CM on changes in QOL over time. These results suggest that CM
may have broad beneficial effects on patients that extend beyond abstinence outcomes and
the duration of provision of external reinforcers. This is an important issue that has bearing
on the generalization and extension of treatment effects, a fundamental question with respect
to CM as well as other drug abuse treatments.
The earlier study,14 however, did not examine the impact of polysubstance dependence on
the relationships between treatment condition and QOL. Because alcohol dependence is so
prevalent in cocaine-dependent patients2–4 and is independently associated with low
QOL, 20, 22–24 patients with dual cocaine and alcohol diagnoses may have poorer overall
quality of life and may show differential treatment response compared to their counterparts
without alcohol dependence. The purpose of this retrospective data analytical study is to
evaluate QOL in a large sample of cocaine abusing outpatients with versus without
comorbid alcohol dependence (AD). Specific aims are to examine (1) differences in baseline
QOL in cocaine treatment outpatients with and without AD, and (2) the impact of CM
versus standard care on changes in QOL over time as a function of AD status.
Method
Participants
A dataset comprised of a total of 393 participants from three randomized clinical trials42–44
was analyzed in the present study. All participants were drawn from one of four community-
based treatment centers located in Connecticut and Massachusetts. The four clinics shared
similar structure, implemented analogous therapeutic approaches, and provided services to
populations of patients with similar characteristics. Across studies, patients were comparable
on QOL scores, mean years of cocaine use, education, age, and employment and marital
status (all ps >.05). Recruitment for the clinical trials occurred between 1998 and 2001,42
2001 and 2002, 43 and 2000 and 2003.44 Although possible, it is unlikely that any individual
participated in more than one trial as the clinics provide services in different localities.
Changes in research assistant staffing were relatively infrequent, and research assistants
were unaware of any instances of repeated participation in trials.
In all three trials, patients were eligible to participate if they were 18 years of age or older,
met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)45 criteria for
cocaine abuse or dependence, were initiating treatment in any of the clinics, and were able to
understand the procedures implemented in the study. Participants were excluded from the
studies if they were suicidal, had medically uncontrolled psychotic or bipolar disorders, or
were in recovery for pathological gambling. Inclusion criteria were unrestrictive to increase
the generalization of the findings. All participants provided written informed consent
approved by the University of Connecticut Health Center Institutional Review Board.
Across the three studies, a total of 482 patients were contacted, and 433 provided informed
consent. Of those who consented, 393 were randomized to a treatment condition. A total of
115 participants were randomized to standard care (SC), and a total of 278 to CM treatment,
as outlined below in the Treatment section.
Procedures
The main goal of the studies on which the present analysis is based42–44 was to assess the
efficacy of CM treatments relative to SC. All three studies also had the following procedural
similarities: (1) randomization to the conditions; (2) assessment measures and intervals; (3)
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treatment duration and intensity; and (4) follow-up intervals and overall duration. Each of
the studies evaluated two CM conditions, which produced longer durations of abstinence
than SC treatment. Because of the procedural, patient and outcome similarities across
studies, all CM conditions were combined for the purposes of this report.
Following informed consent, participants completed a 2-hour interview in which baseline
and demographic data were collected, as well as substance use diagnoses via checklists
derived from the Structured Clinical Interview for the DSM-IV.46 In addition, participants
also completed the Brief Symptom Inventory (BSI) and the Quality of Life Inventory
(QOLI). The BSI is a self-report questionnaire comprised of 53-items evaluating
psychological distress.47 Each item is rated in a 5-point scale, and a Global Symptom Index
(GSI) is calculated from the total score, ranging from 0 to 4, with higher scores indicating
greater distress.
The QOLI16 is a questionnaire aimed at assessing respondent's satisfaction and importance
in 17 domains of life (e.g., health, work, love relationship, friendship) associated with
subjective well-being. In each of the 17 domains, a subscale score is obtained by multiplying
the respondent's importance rating by his or her satisfaction rating. The former is based on a
three-point scale ranging from 0 (not at all important) to 2 (extremely important), and the
latter is based in a seven-point scale ranging from -3 (very dissatisfied) to +3 (very
satisfied). The total QOLI score is calculated by averaging all subscale scores that have
importance ratings greater than zero. Therefore, the QOLI total score reflects well-being in
specific domains considered important from the individual respondent's perspective. This
questionnaire has high test-retest reliability and correlates strongly with other well-being
measures.15, 16
Patients were contacted for follow-up evaluations 1, 3, 6 and 9 months after study intake,
and the QOLI was re-administered. Follow-up completion rates were 84.2%, 81.2%, 73.5%
and 69.0% for the respective evaluations and did not differ by study, site, treatment
condition, or AD status (ps > .05). For completion of the follow-up evaluations, participants
were paid $30-35.
Treatments
Participants were randomly assigned to one of two treatments—SC or CM. In each study,
one third of participants were assigned to SC and two thirds to one of two CM conditions.
Below is a brief description of the SC and CM treatments. For a more complete description,
the reader should refer to the primary sources.42–44
Standard Care Treatment
Standard intensive outpatient treatment in all sites and studies was comprised of group
therapy sessions, AIDS education, coping and life skills training, relapse prevention, and 12-
step treatment. Treatment intensity and frequency varied in accord to patients’ needs. In
general, intensive care lasted 2 to 4 weeks, with group sessions ranging from 3 to 5 times per
week (up to 5 hours per day). Following this phase, treatment was gradually reduced, and
aftercare consisted of a single weekly group session for up to 12 months. Participants also
submitted study breath and urine samples. Up to 21 samples were scheduled over a period of
3 months, and those specimens were tested for cocaine, opioids, and alcohol using an onsite
testing system, OnTrakTestStick (Varian, Walnut Creek, CA), for testing cocaine and
opioids, and an Intoximeter (Intoximeters, Inc., St Louis, Mo.) for assessing alcohol.
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CM Treatment
The CM conditions included the same SC and sample testing as outlined above. In addition,
participants received tangible reinforcers contingent upon objective demonstration of
abstinence and/or completion of goal-related activities. More specifically, two classes of
behaviors were reinforced depending on the study and condition: (1) submission of samples
negative for cocaine, alcohol, and opioids (abstinence from all three drugs concurrently);
and/or (2) completion of selected activities related to the patients’ goal areas (e.g.,
employment, family; see 48). In studies in which both behaviors were reinforced,42, 43 each
behavior was reinforced independently such that abstinence reinforcement did not affect
activity reinforcement, and vice-versa. Reinforcers consisted of opportunities to earn prizes
or vouchers.
Data Analytic Procedure
Independent t-tests and χ2 tests evaluated differences in baseline characteristics between
patients with and without AD. Baseline variables that differed significantly between groups
were included as covariates in subsequent analyses. Initially, univariate analysis of
covariance (ANCOVA) examined the relationship between AD status and QOL, with the
overall baseline QOL score as the dependent variable. AD status, race, and baseline BSI
scores were included as independent variables, and age as a weighted variable. Multivariate
analysis of covariance (MANCOVA) evaluated the association between AD and the 17
QOL subscales, controlling for the same covariates as above.
A repeated measure analysis of variance examined changes in QOL total scores over time.
Independent variables were AD status, race, age, baseline BSI scores, and treatment
condition (CM or non-CM). The interaction between treatment condition and AD status was
also included in the model to determine if patients with and without AD responded
differently to the interventions. All analyses were conducted on SPSS for Windows (v.15).
Results
Baseline and demographic characteristics are presented in Table 1 for patients with (n =
208) and without AD (n = 185). Approximately 29% of individuals from each group were
assigned to SC and 71% to CM, consistent with the study designs. There were no significant
differences between the two groups on most baseline characteristics, except race, age, and
BSI scores. AD patients were more likely to be Caucasian and Native American, older, and
to score higher on the BSI compared to non-AD patients.
Table 2 shows baseline QOL scores for those with and without AD. After controlling for
other variables, ANCOVA revealed significant effects of AD status, F (1,387) = 6.57, p = .
01, with AD patients having lower QOL scores than non-AD patients. BSI scores were
significantly and inversely related to QOL total scores, F (1, 387) = 51.34, p < .001. Race
was also related to baseline QOL scores, with Caucasians having the lowest mean (SE) QOL
score, 0.76 (0.17), and Native Americans and Hispanics the highest, 1.99 (0.74) and 1.93
(0.29), respectively. African Americans had intermediate QOL scores, 1.73 (0.13).
The MANCOVA evaluating baseline QOL subscale scores also revealed a significant effect
of AD status, F (17,371) = 1.80, p = .03. Table 2 shows weighted means for the 17 subscales
as a function of AD status. Six of the subscales differed significantly at p < .05 by AD
status: work, recreation, love, friendship, relationship with children, and home. In each case,
patients with AD had lower scores than those without AD. Again, race and baseline BSI
scores were associated with individual subscale scores, F (51, 1119) = 1.95, p < .001 and F
(17,371) = 5.81, p < .001, respectively. All 17 subscale scores were significantly (p < .01)
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and inversely associated with BSI scores, and all but five (work, recreation, friendship,
neighborhood and community) differed by race (data not shown).
In the repeated measures ANOVA, neither AD status nor its interaction with treatment
condition were associated with changes in QOL scores over time, F (4, 206) = 1.19, p = .32
and F (4, 206) = 0.62, p = .65, respectively. Treatment condition was related to changes in
QOL scores, F (4, 206) = 2.57, p = .04, with patients assigned to the CM treatments showing
increases in QOL over time and those assigned to SC evidencing no significant change (see
Figure 1). Other covariates were not significant.
Discussion
To our knowledge, this is the first study to examine QOL at baseline and over time in
cocaine abusing outpatients with and without comorbid AD. AD patients had reduced
baseline QOL scores compared to patients without AD. These results are consistent with
other studies reporting that cocaine dependent individuals with comorbid AD have greater
behavioral, psychological, and psychiatric impairment than individuals presenting with
cocaine dependence alone.2–7
As mentioned before, there are relatively few examples of QOL research in the drug abuse
literature. In one study in cocaine dependent patients, Havassy and Arns27 reported that
hospitalized psychiatric patients with cocaine dependence had lower QOL than psychiatric
patients with AD or other substance dependences. Comparison between that study and this
one is complicated due to methodological differences (e.g., population, QOL assessment
used). Nevertheless, our finding that patients with concomitant cocaine-alcohol use disorder
have poorer QOL at treatment initiation than individuals presenting with cocaine abuse
alone—a group known to have poor QOL—is concerning especially in light of the
extremely high rates of co-occurring cocaine and alcohol use disorders in US population in
general,1, 49 as well as community treatment settings.2–4
The analysis of the 17 subscales of the QOLI shows that patients with comorbid AD score
lower than patients without AD on 6 of the 17 subscales primarily related to interpersonal
relationships at treatment initiation. Although these results should be interpreted with
caution due to multiple testing, they indicate that concomitant AD may have a greater
negative impact on social relationships than some other domains. Clinical repercussions
might be that patients with concurrent cocaine and alcohol use disorders may need greater
social functioning support than some other groups of substance abusers. Knowledge of this
deficit might help clinicians develop more targeted treatment plans for this patient
population that specifically address social relations.
In regards to the relationship between CM and QOL, our analysis suggests that CM was
associated with gains in QOL over time regardless of the presence of AD. In contrast, QOL
did not significantly change over time in SC patients. In a previous study,50 we reported that
cocaine treatment patients with and without comorbid AD responded equally well to CM
treatment with respect to improved abstinence and decreased psychosocial problems as
assessed by the Addiction Severity Index. The results presented here complement those
findings using another outcome measure. Cocaine abusing patients with and without AD
appear to respond similarly to CM across several QOL domains.
Although efficacious in improving end of treatment outcomes, CM benefits are not always
maintained long-term. Further, improvements on secondary outcomes with CM are not
consistently observed. In the present study, CM-related improvements in QOL over time
were maintained through the Month 9 follow-up. In another study based on a retrospective
analysis of the three studies examined here,50 we reported that CM-related improvements in
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psychosocial functioning in patients with AD were maintained through Month 9. Together,
these studies provide some evidence that the benefits produced by exposure to CM treatment
can extend to other areas of functioning, as well as beyond the treatment period.
Limitations of this study include the use of ANOVA to examine QOLI scores over time
when there are missing data. Another limitation is the use of a combined sample from three
clinical trials, which increases heterogeneity. Therefore, results should be interpreted with
caution. Although there were some differences in the CM treatment applied across the trials
(target behavior and reinforcer magnitude or type), all three clinical trials42–44 shared
substantial similarities in terms of experimental procedures, goals, and treatment effects (see
Method section and individual reports for more details). That long-term outcomes were
limited to 9 months is also a limitation as longer follow-up would be preferable.
Strengths of this study are the broad inclusion criteria for participation, large sample size,
and the inclusion of CM in combination with standard care in community-based treatment
center clinics. These factors are likely to increase the generalization of these results. Another
strength is the randomization of patients to study conditions.
In summary, although there has been a great increase in the number of studies involving
QOL in the biomedical and health treatment research in general, few studies have used QOL
indices to assess patient's well being and treatment outcomes in drug abuse research.11, 18, 20
This study sheds some light on the QOL of cocaine abusers with and without AD, a
population on which research involving QOL has been scarce. The results presented here
show that there are significant differences between the QOL of outpatient cocaine abusers
with and without comorbid AD. At the time treatment is sought, cocaine abusing patients
with AD have lower QOL total score as well as lower scores on several subscales related to
social relationships than patients without AD. Furthermore, results indicate that cocaine
abusing patients with and without AD showed similar improvement in QOL during CM
treatment and beyond. Future studies involving this population might investigate the long
term outcomes produced by CM over more extended periods of time.
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FIGURE 1.
Quality of Life Inventory Scores over time. Values represent weighted mean scores obtained
by alcohol (squares) and non-alcohol (circles) dependent patients. Open and closed symbols
depict contingency management (CM) and standard care (SC) treatment groups,
respectively.
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TABLE 1
Demographic and baseline characteristics by alcohol dependence status
Variable Non-Alcohol Dependent (n =
185)
Alcohol Dependent (n = 208) Statistic (df) p
Treatment condition, % (n) χ2(1) = 0.00 .98
    Standard Care 29.2 (54) 29.3 (61)
    Standard Care + CM 70.8 (131) 70.7 (147)
Agea 34.83 ± 7.50 37.65 ± 7.62 t(391) = -3.70 <.001
Annual incomea $9,334.74 ± 12,943 9,906.75 ± 16,416 t(391) = -3.80 .70
Brief Symptom Inventory, Global Severity
Index score
0.76 ± 0.68 1.02 ± 0.69 t(391) = -3.71 <.001
Years of Educationa 11.61 ± 1.53 11.56 ± 1.90 t(391) = 0.26 .80
Gender,% (n) χ2(1) = 0.92 .34
    Male 47.6 (88) 52.4 (109)
    Female 52.4 (97) 47.6 (99)
Race,% (n) χ2(3) = 8.06 .04
    Caucasian 29.7 (55) 38.9 ( 81)
    African American 56.2 (104) 49.0 (102)
    Hispanic 13.5 (25) 9.1 (19)
    Native American 0.5 (1) 2.9 (6)
Marital status,% (n) χ2(2) = 0.55 .76
    Single 55.1 (102) 51.9 (108)
    Other 33.0 (61) 34.1 (71)
    Married 11.9 (22) 13.9 (29)
Site, % (n) χ2(3) = 7.55 .06
    A 9.2 (17) 6.7 (14)
    B 26.5 (49) 39.4 (82)
    C 33.5 (62) 28.8 (60)
    D 30.8 (57) 25.0 (52)
Years of cocaine useb 10.33 ± 6.9 11.35 ± 7.9 F(1,390) = 2.17 .14
Note. Values are percentages (ns in parentheses) unless otherwise specified. CM = contingency management.
a
Mean ± standard deviation
bAge adjusted means and standard deviations
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